NCT06643260View on ClinicalTrials.gov

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

705

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions

Plaque Psoriasis

Interventions

DRUG

piclidenoson

Piclidenoson is a selective A3AR agonist, supplied as tablets.

DRUG

Placebo

Inactive control

Sponsors

Lead Sponsor

Can-Fite BioPharma

All Listed Sponsors

lead

Can-Fite BioPharma

INDUSTRY